CX-5461,1138549-36-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CX-5461

CAS No. : 1138549-36-6

MCE 国际站：CX-5461

产品活性：CX-5461 是一种有效，口服的 rRNA 合成抑制剂。在 HCT-116，A375 和 MIA PaCa-2 细胞中抑制 RNA 聚合酶 I 驱动的 rRNA 转录，IC₅₀ 为 142，113 和 54 nM。

研究领域：Cell Cycle/DNA Damage

作用靶点：DNA/RNA Synthesis

In Vitro: CX-5461 is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC₅₀s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC₅₀, ≥25 μM). CX-5461 has modest inhibition on DNA replication and protein translation. CX-5461 also exhibits broad antiproliferative activity against a panel of human cancer cell lines, with a mean EC₅₀ of 147 nM, but has minimal effect on viability of nontransformed human cells, with EC₅₀ values of appr 5000 nM. EC₅₀s of CX-5461 for HCT-116, A375, and MIA PaCa-2 cell lines are 167, 58, and 74 nM, respectively. CX-5461 induces autophagy and senescence in solid tumor cancer cells, rather than apoptosis, through a p53-independent process. Eμ-Myc lymphoma cells from tumor-bearing mice are exquisitely sensitive to CX-5461 with an IC₅₀ of 27.3 nM ± 8.1 nM for Pol I transcription after 1 hr and IC₅₀ of 5.4 nM ± 2.1 nM for cell death after 16 hr. CX-5461 activates p53 via the nucleolar stress response in Eμ-MycLymphoma Cells.

In Vivo: CX-5461 displays antitumor activity against human solid tumors in murine xenograft models. CX-5461 (50 mg/kg, p.o.) shows significant MIA PaCa-2 growth inhibition with TGI equal to 69% on day 31 and 79% TGI on A375 on day 32. CX-5461 (50 mg/kg, p.o.) inhibits the Eμ-Myc tumor cells with 84% repression in Pol I transcription at 1 hr posttreatment in C57BL/6 mice. CX-5461 also induces a rapid reduction in tumor burden in the lymph nodes and a concomitant reduction of spleen size to within the normal range.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Heterocyclic Compound Library  |  Cycloheximide  |  Actinomycin D  |  Oxaliplatin  |  Gemcitabine  |  Carboplatin  |  Bleomycin sulfate  |  Mitomycin C  |  Cytarabine  |  Methotrexate  |  ART558  |  Streptozotocin  |  Anisomycin  |  Fludarabine  |  Thymidine  |  Hydroxyurea  |  Remdesivir  |  Daunorubicin hydrochloride  |  Brequinar  |  Capecitabine  |  Branaplam  |  α-Amanitin  |  Folic acid  |  Urolithin A  |  Epirubicin hydrochloride  |  Plicamycin  |  Levofloxacin  |  L-Asparaginase

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds